[Correlation between intrathecal opioids and gynecomastia -- a case report]

Area of Science:

• Pain Management
• Endocrinology
• Pharmacology

Background:

• Intrathecal opioid administration is a common treatment for chronic non-malignant pain.
• Potential side effects of this delivery method, including hormonal alterations, require investigation.
• Gynecomastia, a rare condition, is explored as a possible consequence.

Observation:

• A case study of a 49-year-old male with chronic pain receiving intrathecal opioids is presented.
• The patient developed gynecomastia concurrently with the initiation of opioid therapy.
• A review of existing literature and animal studies supports a potential causal link.

Findings:

• A correlation was observed between the commencement of intrathecal opioid application and the onset of gynecomastia.
• Evidence from historical publications and recent animal research supports the hypothesis of a link.
• The findings suggest intrathecal opioids may disrupt androgen hormone balance.

Implications:

• Further research is necessary to confirm the clinical suspicion of a link between intrathecal opioids and gynecomastia.
• Testing the estrogen-testosterone ratio is recommended for patients with opioid-induced gynecomastia.
• Early testosterone substitution may prevent the progression of opioid-induced gynecomastia.